Activity of voriconazole against Candida albicans and Candida krusei isolated since 1984

International Journal of Antimicrobial Agents

Volumn 16, Issue 3, 2000, Pages 205-209

  Lee, Jenny K ^a   Peters, Dixie ^a   Obias, Arlene A ^a   Noskin, Gary A ^a   Peterson, Lance R ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

Candida albicans; Candida krusei; Fluconazole resistance; Voriconazole

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CANDIDA ALBICANS; CANDIDA KRUSEI; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; DRUG SENSITIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; DRUG RESISTANCE, MICROBIAL; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

EID: 0033708581     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00191-6     Document Type: Article

References (24)

1. Trends in antifungal susceptibility among Candida sp. Urinary isolates from 1994 and 1998
2. Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center
3. Efficacy of UK-109,496, a new azole antifungal agent, in an experimental model of invasive aspergillosis
4. In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications
5. In vitro evaluation of voriconazole against some clinically important fungi
6. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis
7. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens
8. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Clinical efficacy in acute invasive aspergillosis
9. Current and emerging azole antifungal agents
10. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species
11. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant species
12. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.
13. Voriconazole against fluconazole-susceptible and -resistant Candida isolates: In-vitro efficacy compared with that of itraconazole and ketoconazole
14. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis
15. Initial use of a broth microdilution method suitable for in vitro testing of fungal isolates in a clinical microbiology laboratory
16. Effect of incubation time and buffer concentration on In vitro activity of antifungal agents against Candida albicans
17. Optimizing voriconazole susceptibility testing of Candida: Effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility
18. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei
19. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection
20. Resistance to amphotericin B: Emerging clinical and microbiological patterns
21. Multiple resistance mechanisms to azole antifungals in yeast clinical isolates
22. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR
23. Reversible fluconazole resistance in Candida albicans, a potential in vitro model